United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
United Therapeutics (UTHR) announced the presentation of ten posters and presentations across its commercial and development portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting taking place April 27-30, 2025 in Boston.
The presentations cover various topics including xenotransplantation developments, pharmacokinetic studies of Ralinepag, cardiac xenotransplantation outcomes, and pulmonary hypertension research. Key highlights include studies on multi-gene-edited pig lungs, pig-to-baboon lung transplantation, and safety data on low-dose oral Treprostinil in PH-HFpEF patients.
The company will also host a sponsored symposium titled 'The Pros, The Cons, the Wicked Good EVLP Debates' featuring experts from leading medical institutions discussing ex vivo lung perfusion.
United Therapeutics (UTHR) ha annunciato la presentazione di dieci poster e presentazioni nel suo portafoglio commerciale e di sviluppo durante il 45° Congresso Annuale della Società Internazionale per il Trapianto di Cuore e Polmoni (ISHLT), che si svolgerà dal 27 al 30 aprile 2025 a Boston.
Le presentazioni coprono vari argomenti, tra cui sviluppi nella xenotrapianto, studi farmacocinetici di Ralinepag, risultati del trapianto cardiaco da xenotrapianto e ricerche sull'ipertensione polmonare. I punti salienti includono studi su polmoni di maiali modificati geneticamente, trapianto di polmoni da maiale a babbuino e dati di sicurezza su Treprostinil orale a bassa dose nei pazienti con PH-HFpEF.
La compagnia ospiterà anche un simposio sponsorizzato intitolato 'I Pro, I Contro, i Dibattiti Wicked Good EVLP', con esperti di importanti istituzioni mediche che discuteranno della perfusione polmonare ex vivo.
United Therapeutics (UTHR) anunció la presentación de diez carteles y presentaciones en su cartera comercial y de desarrollo en el 45° Congreso Anual de la Sociedad Internacional de Trasplante de Corazón y Pulmón (ISHLT), que se llevará a cabo del 27 al 30 de abril de 2025 en Boston.
Las presentaciones abarcan varios temas, incluidos los desarrollos en xenotrasplante, estudios farmacocinéticos de Ralinepag, resultados de xenotrasplante cardíaco y investigación sobre hipertensión pulmonar. Los aspectos más destacados incluyen estudios sobre pulmones de cerdos editados genéticamente, trasplante de pulmones de cerdo a babuino y datos de seguridad sobre Treprostinil oral a baja dosis en pacientes con PH-HFpEF.
La compañía también organizará un simposio patrocinado titulado 'Los Pros, Los Contras, los Debates Wicked Good de EVLP', con expertos de instituciones médicas líderes discutiendo la perfusión pulmonar ex vivo.
유나이티드 테라퓨틱스 (UTHR)는 제45회 국제 심장 및 폐 이식 학회 (ISHLT) 연례 회의에서 상업 및 개발 포트폴리오의 10개의 포스터와 발표를 발표한다고 발표했습니다. 이 회의는 2025년 4월 27일부터 30일까지 보스턴에서 열립니다.
발표 내용은 이식 동물 개발, 라리네파그의 약리학적 연구, 심장 이식 결과 및 폐 고혈압 연구를 포함한 다양한 주제를 다룹니다. 주요 하이라이트로는 다중 유전자 편집 돼지 폐 연구, 돼지에서 바부인으로의 폐 이식, PH-HFpEF 환자에서 저용량 경구 트레프로스틴일의 안전성 데이터가 포함됩니다.
회사는 '장점, 단점, 기막힌 EVLP 토론'이라는 제목의 후원 심포지엄도 개최할 예정이며, 주요 의료 기관의 전문가들이 생체 외 폐 관류에 대해 논의할 것입니다.
United Therapeutics (UTHR) a annoncé la présentation de dix affiches et présentations dans son portefeuille commercial et de développement lors de la 45e Réunion Annuelle de la Société Internationale de Transplantation de Cœur et de Poumon (ISHLT), qui se tiendra du 27 au 30 avril 2025 à Boston.
Les présentations couvrent divers sujets, y compris les développements en xenotransplantation, des études pharmacocinétiques sur le Ralinepag, les résultats de la xenotransplantation cardiaque et la recherche sur l'hypertension pulmonaire. Les points forts incluent des études sur les poumons de porcs modifiés par plusieurs gènes, la transplantation de poumons de porc à babouin et des données de sécurité sur le Treprostinil oral à faible dose chez les patients atteints de PH-HFpEF.
L'entreprise organisera également un symposium sponsorisé intitulé 'Les Avantages, Les Inconvénients, les Débats Wicked Good EVLP', avec des experts d'institutions médicales de premier plan discutant de la perfusion pulmonaire ex vivo.
United Therapeutics (UTHR) gab die Präsentation von zehn Postern und Präsentationen aus seinem kommerziellen und Entwicklungsportfolio auf dem 45. Jahreskongress der International Society for Heart and Lung Transplantation (ISHLT) bekannt, der vom 27. bis 30. April 2025 in Boston stattfindet.
Die Präsentationen decken verschiedene Themen ab, darunter Entwicklungen im Xenotransplantation, pharmakokinetische Studien zu Ralinepag, Ergebnisse der kardialen Xenotransplantation und Forschung zur pulmonalen Hypertonie. Zu den wichtigsten Highlights gehören Studien zu mehrgeneditieren Schweinelungen, dem Lungentransplantation von Schwein zu Pavian und Sicherheitsdaten zu niedrig dosiertem oralem Treprostinil bei PH-HFpEF-Patienten.
Das Unternehmen wird auch ein gesponsertes Symposium mit dem Titel 'Die Vor- und Nachteile, die großartigen EVLP-Debatten' ausrichten, bei dem Experten führender medizinischer Institutionen über die ex vivo Lungenperfusion diskutieren.
- Advancing research in xenotransplantation technology with multiple studies
- Expanding clinical data for Treprostinil in new patient populations
- Demonstrating progress in organ transplantation alternatives
- None.
“The additional data across our portfolio presented at this year’s meeting highlight our commitment to furthering the science and standards of care in pulmonary hypertension and progressing the future of xenotransplantation,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “We look forward to a collaborative exchange with fellow researchers, clinicians, and thought leaders to collectively advance our understanding and push the boundaries of medical innovation.”
Posters and presentations include:
Oral Session 05 – Donor Lung Engineering: Recent Developments and Continued Challenges, Sunday, April 27, 3:36 – 3:44 p.m. ET: 28 – Selectin and Integrin Blockade in Multi-Gene-Edited Pig Lungs Perfused with Human Blood. Presented by Zahra Habibabady, Massachusetts General Hospital.
Oral Session 05 – Donor Lung Engineering: Recent Developments and Continued Challenges, Sunday, April 27, 3:48 – 3:56 p.m. ET: 29 – Outcomes in 10GE Pig-to-Baboon Xenogeneic Lung Transplantation. Presented by Sho Takemoto, Massachusetts General Hospital.
Poster Session 1. Pharmacy, Sunday, April 27, 6:00 – 7:00 p.m. ET: 803 – Developing Models for New Drugs in PAH: A Pharmacokinetic Simulation of Ralinepag. Presented by Andrew Stine, United Therapeutics.
Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left Ventricular Global Longitudinal Strain in the Second Genetically Modified Porcine to Human Cardiac Xenotransplantation. Presented by Sarah Leventhal, University of
Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 448 – Clinical Correlations with Cardiac Power Output and Left Ventricular Global Longitudinal Strain in the Second Genetically Modified Porcine to Human Cardiac Xenotransplantation. Presented by Sarah Leventhal, University of
Oral Session 22 – Tolerance or Xenotransplantation: Who Wins the Race in Heart Transplantation?, Tuesday, April 29, 10:36 – 10:44 a.m. ET: 132 – Ischemia Minimization is Protective for Both GalTKO and 10GE Porcine Hearts in an Ex Vivo Working Heart Model. Presented by Victoria Diaz, Massachusetts General Hospital.
Poster Session 3. Pulmonology, Tuesday, April 29, 4:30 – 5:30 p.m. ET: 1638 – Safety of Low-Dose Oral Treprostinil in PH-HFpEF Supports Use in Patients with PAH with Cardiovascular Comorbidities. Presented by Raymond Benza, Mount Sinai.
Poster Session 3. Pulmonology, Tuesday, April 29, 4:30 - 5:30 p.m. ET: 1639 – PHINDER (Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection) - Interim Analysis of Baseline Features. Presented by Oksana Shlobin, Inova Medical Group.
Poster Session 3. Cardiothoracic Surgery, Tuesday, April 29, 4:30 – 5:30 p.m. ET: 1415 – Correlation of Left Ventricular Global Longitudinal Strain with NT-proBNP in the First and Second Genetically Modified Porcine to Human Xeno Heart Transplants. Presented by Javier Galindo, University of
Mini Oral 11: Transplant Ethics and Lung Outcomes, Tuesday, April 29, 4:36 – 4:40 p.m. ET: 385 – Analyzing Healthcare Costs and Predictors of High Cost in Lung Transplant Recipients with and without Ex Vivo Lung Perfusion Using Linked Data. Presented by Rajat Walia, St. Joseph’s Hospital and Medical Center.
Sponsored events include:
Sponsored Symposium: “The Pros, The Cons, the Wicked Good EVLP Debates,” on Sunday April 27, from 11:45 a.m. to 12:45 p.m. ET. Moderated by Caitlin Demarest, Vanderbilt University Medical Center and Jacob Klapper, Duke University Medical Center, with a debate by Sravanthi Nandavaram, Massachusetts General Hospital; Pedro Catarino, Cedars Sinai; Jasleen Kukreja, University of California San Francisco; and Mani Daneshmand, Emory University.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 4, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404949053/en/
For Further Information Contact:
Dewey Steadman at (202) 919-4097 (media/investors)
Harry Silvers at (301) 578-1401 (investors)
https://ir.unither.com/contact-uthr/
Source: United Therapeutics Corporation
FAQ
What key research will UTHR present at ISHLT 2025 regarding xenotransplantation?
What are the dates and location of UTHR's presentations at ISHLT 2025?
What is the focus of UTHR's Treprostinil research being presented?
What is the topic of UTHR's sponsored symposium at ISHLT 2025?
